Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYT-200 in metastatic solid tumors
NCT04666688Phase 2Completed
- Sponsor
- PureTech Health
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of lyt-200 in metastatic solid tumor, pancreatic cancer (PC), urothelial carcinoma (UC) and 2 more (3 arms), sponsored by PureTech Health. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year, Incidence of Dose Limiting Toxicities at 1 year and 2 more. Started Dec 2020; status: completed.
02
Drugs
lyt-200
03
Conditions
metastatic solid tumorpancreatic cancer (PC)urothelial carcinoma (UC)head and neck cancer (HNC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04666688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666688.